ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01672 ASCLETIS-B

Noon Closed 05-06 12:05:00

16.450

-0.270

-1.61%

High17.110	Low16.290	Vol590.00K
Open16.800	D1 Closing16.720	Amplitude4.90%
Mkt Cap17.45B	Tradable Cap17.45B	Total Shares1.06B
T/O9.83M	T/O Rate0.06%	Tradable Shares1.06B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"ASCLETIS-B","latestPrice":16.45,"timestamp":1778040300004,"preClose":16.72,"halted":0,"volume":590000,"delay":0,"changeRate":-0.01614832535885165,"floatShares":1061000000,"shares":1061000000,"eps":-0.4252935307438547,"marketStatus":"Noon Closed","change":-0.27,"latestTime":"05-06 12:05:00","open":16.8,"high":17.11,"low":16.29,"amount":9828185,"amplitude":0.049043,"askPrice":16.45,"askSize":3000,"bidPrice":16.4,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.4309242745986099,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778043600000},"marketStatusCode":3,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":16.72,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":0.749855,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672/tweets","defaultTab":"tweets","newsList":[{"id":"1175594296","title":"Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations","url":"https://stock-news.laohu8.com/highlight/detail?id=1175594296","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175594296?lang=en_us&edition=fundamental","pubTime":"2026-05-06 09:14","pubTimestamp":1778030064,"startTime":"0","endTime":"0","summary":"Major Developments: LEADS BIOLABS-B (09887) will prioritize the clinical development of LBL-047 for Sjögren's syndrome, systemic lupus erythematosus, and dermatomyositis. ASCLETIS-B (01672) will...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159875","09887","01201","160640","VXUS","BK1574","BK1161","HK0000252152.HKD","BK1116","HK0000500386.USD","BK4588","HK0000252160.HKD","399941","06938","BK4585","000941.SH","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174217966","title":"ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=1174217966","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174217966?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:20","pubTimestamp":1778026854,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","LU0997586861.USD","BK4144","BK1515","ECO","BK1161","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113627205","title":"Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone","url":"https://stock-news.laohu8.com/highlight/detail?id=1113627205","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113627205?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:02","pubTimestamp":1778025777,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. (Ascletis) has issued a voluntary announcement confirming three poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled for 12–15 May 2026 in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633975137","title":"Ascletis reports Phase I data for ASC47 obesity drug at ECO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633975137","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633975137?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:00","pubTimestamp":1778025645,"startTime":"0","endTime":"0","summary":"Ascletis Pharma announced it will present new posters at European Congress on Obesity  in Istanbul on May 12-15, 2026, including first-in-human Phase I results for obesity candidate ASC47.Early clinical findings showed ASC47 combined with semaglutide delivered greater weight loss than semaglutide alone, supporting a combination strategy aimed at weight reduction while preserving muscle.Preclinical data to be presented for once-monthly obesity peptides ASC36 and ASC35 indicated longer-lasting activity than established comparators, with stronger weight-loss effects in animal models.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Infor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL737TkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102994678","title":"ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=1102994678","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102994678?lang=en_us&edition=fundamental","pubTime":"2026-04-30 12:08","pubTimestamp":1777522097,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) rose more than 3% during the morning trading session. At the time of writing, the stock was up 2.06%, trading at HK$16.85 with a turnover of HK$7.3672 million. The company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK4588","BK4585","BK1574","VXUS","01477","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140272132","title":"ASCLETIS-B to Present Multiple Project Findings at ADA 2026 Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=1140272132","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140272132?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:12","pubTimestamp":1777507933,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced it will present multiple projects via poster sessions at the American Diabetes Association's 2026 Scientific Sessions, scheduled for June 5-8, 2026, in New Orleans,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01672","BK1191","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631057570","title":"Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2631057570","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631057570?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:10","pubTimestamp":1777507800,"startTime":"0","endTime":"0","summary":"HONG KONG, April 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  announces today poster presentations highlighting multiple programs at the American Diabetes Association's  2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of ASC39, aneloralintide-like selective and potent oral small molecule amylin receptor agonist for the treatment of obesity.Title: ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity. Title: Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity. Additional information about the ADA's 2026 Scientific Sessions is available at the ADA meeting website .","market":"us","thumbnail":"https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2935737/Ascletis_Pharma_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-to-present-data-on-multiple-programs-at-the-american-diabetes-associations-2026-scientific-sessions-302757320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","01672","BK4107","BK4117","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575965","title":"Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575965","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631575965?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:01","pubTimestamp":1777507316,"startTime":"0","endTime":"0","summary":"Ascletis scheduled new data presentations for American Diabetes Association 2026 Scientific Sessions in New Orleans on June 7, 2026.Late-breaking preclinical results for ASC39 are set to be presented, supporting its potential as an oral amylin receptor agonist candidate for obesity.Phase II findings for oral GLP-1 candidate ASC30 will be presented, indicating meaningful weight loss with improved gastrointestinal tolerability versus placebo.Nonhuman primate data for ASC37 oral tablets will be presented, indicating the triple-agonist peptide achieved measurable oral absorption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL9Zs3gV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123125754","title":"歌礼制药-B（01672）2025年业绩：营收达0.02028亿元，净亏损3.5988亿元，三大管线研发推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1123125754","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123125754?lang=en_us&edition=fundamental","pubTime":"2026-04-29 22:08","pubTimestamp":1777471724,"startTime":"0","endTime":"0","summary":"歌礼制药-B（股票代码：01672，注册成立于开曼群岛，主要在香港开展业务）于近日披露2025年度报告，显示公司在代谢性疾病、免疫性疾病及探索性适应症三大研发管线均取得多项进展，并保持对新药研发的持续投入。以下为本年度经营与财务状况的主要概览： 一、营运及财务表现   1. 收入与利润：   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"歌礼制药-B（01672）2025年业绩：营收达0.02028亿元，净亏损3.5988亿元，三大管线研发推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124616358","title":"HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124616358","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124616358?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:06","pubTimestamp":1777342004,"startTime":"0","endTime":"0","summary":"Biotech stocks jumped in Hong Kong market. Wuxi Apptec soared 14% as 1Q net profit rose 26.7%; Junshi Bio up 8%; Asymchem up nearly 7%; Wuxi XDC up 5%; Pharmaron up 4%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"80c6b79ff83106ff1da4986263b7db82","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02269","06606","09995","09606","06978","02268","09688","09966","02359","03759","03347","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630456396","title":"Sagimet Biosciences Shares Rise With Focus on Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2630456396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630456396?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:02","pubTimestamp":1777291320,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences shares rose after the company said it would focus on advancing development of its acne treatment in the U.S.The stock climbed 29% to $7.55 in premarket trading Monday. Through Friday's close, the stock had ticked down 1% this year.The clinical-stage biopharmaceutical company said it plans to start a U.S. Phase 3 trial of denifanstat, a treatment for moderate to severe acne, in the second half of this year.The decision marks a broader strategic shift to prioritize Sagimet's dermatology business while pursuing nondilutive funding options for its program in the liver disease MASH, or metabolic dysfunction-associated steatohepatitis, Chief Financial Officer Thierry Chauche said.Sagimet had also been developing a combination of denifanstat and resmetirom to treat MASH. The company reported the completion of a Phase 1 trial in December 2025, and expects the combination treatment to be ready for a Phase 2 trial in the second half of this year.In January, Sagimet's license ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT","BK1515","BK1574","01672","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164887151","title":"ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=1164887151","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164887151?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:12","pubTimestamp":1777248751,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) has announced that patient enrollment has been completed for its 13-week US Phase II clinical study (NCT07321678) evaluating the oral small-molecule GLP-1 receptor agonist ASC30...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","01477","BK1161","BK1515","BK4144","BK4590","GLP","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630327603","title":"Ascletis Completes Enrollment in U.S. Phase Ii Study of Asc30, an Oral Small Molecule Glp-1R Agonist, for the Treatment of Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2630327603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630327603?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:10","pubTimestamp":1777248600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA8CYJT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","01672","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630332946","title":"Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332946","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630332946?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:00","pubTimestamp":1777248041,"startTime":"0","endTime":"0","summary":"Ascletis completed enrollment in a 13-week U.S. Phase II trial of ASC30, its once-daily oral small-molecule GLP-1 receptor agonist, in 100 patients with type 2 diabetes.Topline results have not been presented yet; data are expected in Q3 2026.Trial is designed to assess whether ASC30 can improve blood sugar control versus placebo, with additional readouts on weight change and overall safety.Program expansion adds a second major indication for ASC30 beyond obesity, positioning it for a larger metabolic disease market opportunity.Ascletis expects to seek FDA clearance to start U.S. Phase III trials in obesity by end-Q3 2026, following previously disclosed Phase II obesity results from December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL1rys5H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190075292","title":"ASCLETIS-B Shares Surge Over 4% in Morning Session as Key Pipeline Drug ASC30 Nears Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1190075292","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190075292?lang=en_us&edition=fundamental","pubTime":"2026-04-24 11:14","pubTimestamp":1777000467,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) rose more than 4% in morning trading. At the time of writing, the stock was up 3.46% to HK$18.82, with a turnover of HK$21.991 million. The company previously announced the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","III","BK1515","BK4588","BK4585","BK1574","VXUS","01477","BK4134","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165196464","title":"HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165196464","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165196464?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:32","pubTimestamp":1776915127,"startTime":"0","endTime":"0","summary":"HK biotech stocks fell. Akeso down 12%; Remegen, Zai Lab, KeyMed and Junshi down 7%; Lepu and Innocare down 6%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02359","03759","02137","06606","06978","09606","03347","09995","02162","09926","02268","09688","09966","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628531347","title":"Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2628531347","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628531347?lang=en_us&edition=fundamental","pubTime":"2026-04-18 21:05","pubTimestamp":1776517538,"startTime":"0","endTime":"0","summary":"Ascletis Pharma (SEHK:1672) announced the selection of its ASC30_39 fixed dose combination obesity therapy candidate for clinical development. The company plans to file an IND with the U.S. FDA in the third quarter of 2026.\nSee our latest analysis for Ascletis Pharma.\nThat obesity announcement comes after a strong run in the shares, with the latest price at HK$18.48, a 30 day share price return of 25.03% and a 1 year total shareholder return of 274.09%. This suggests momentum has been...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/assessing-ascletis-pharma-sehk1672-valuation-after-asc3039-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/assessing-ascletis-pharma-sehk1672-valuation-after-asc3039-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK4588","01672","BK4585","LABU","IND","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102730668","title":"ASCLETIS-B Nears Previous Peak, But Why Are Investors Staying on the Sidelines?","url":"https://stock-news.laohu8.com/highlight/detail?id=1102730668","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102730668?lang=en_us&edition=fundamental","pubTime":"2026-04-18 12:46","pubTimestamp":1776487561,"startTime":"0","endTime":"0","summary":"Since October of last year, the Hong Kong stock market's pharmaceutical sector has undergone a significant correction. Initially, this downturn was primarily driven by waning market sentiment and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1515","01672","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195869971","title":"ASCLETIS-B Shares Surge Nearly 5% in Afternoon Trading, Approaching All-Time High as GLP-1 and Amylin Combo Enters Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1195869971","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195869971?lang=en_us&edition=fundamental","pubTime":"2026-04-17 14:34","pubTimestamp":1776407662,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) rose nearly 5% in afternoon trading, reaching a high of HK$18.68, close to its historical peak of HK$18.75. At the time of writing, the stock was up 4.73% to HK$18.6, with a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4144","01672","BK4585","BK1161","BK4588","BK4590","VXUS","BK1191","GLP","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626597860","title":"Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626597860","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626597860?lang=en_us&edition=fundamental","pubTime":"2026-04-09 06:22","pubTimestamp":1775686966,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Ascletis Pharma Inc.'s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/analysts-are-optimistic-well-see-a-profit-from-ascletis-phar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/analysts-are-optimistic-well-see-a-profit-from-ascletis-phar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK4139","01672","ASCLF","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":-0.0153},{"period":"3month","weight":0.1977},{"period":"6month","weight":0.7545},{"period":"1year","weight":1.5527},{"period":"ytd","weight":0.468}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.0311},{"period":"3month","weight":-0.0353},{"period":"6month","weight":-0.0222},{"period":"1year","weight":0.1508},{"period":"ytd","weight":0.0105}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.5,"avgChangeRate":0.008558},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"ASCLETIS-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCLETIS-B,01672,ASCLETIS-B股票,ASCLETIS-B股票老虎,ASCLETIS-B股票老虎国际,ASCLETIS-B行情,ASCLETIS-B股票行情,ASCLETIS-B股价,ASCLETIS-B股市,ASCLETIS-B股票价格,ASCLETIS-B股票交易,ASCLETIS-B股票购买,ASCLETIS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}